Comparison of Reportable Cancers: CoC, SEER, NPCR, and CCCR

CoC	SEER	NPCR	CCCR
1. Behavior code of 2 or 3 in ICD-O-3; or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008).	1. Behavior code of 2 or 3 in ICD-O-3.2 plus the ICD-O-3.2 updates posted on the NAACCR website or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008).	1. Behavior code 2 or 3 in ICD-O-3.2; behavior code 3 in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008) (2010+); behavior code 2 or 3 in WHO Classification of Tumours 5th Ed. (2022+) (Refer to instructions provided by NPCR for detailed information.)	1. Behavior code of 2 or 3 in ICD-O-3; or, for 2010 and later diagnoses, behavior code 3 according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008).
2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors, including juvenile astrocytoma (M9421/3)* for primary sites as defined in the Primary Site Codes for Non-Malignant Primary Intracranial and Central Nervous System Tumor table.	2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors, including juvenile astrocytoma (M9421/3)* for primary sites as defined in the Primary Site Codes for Non-Malignant Primary Intracranial and Central Nervous System Tumor table.	2. Primary intracranial and central nervous system tumors behavior code 0 or 1, including juvenile astrocytoma (M9421/3)* for primary sites defined in the Primary Site Codes for Non-Malignant Primary Intracranial and Central Nervous System Tumor table (2004+).	2. Non-malignant (behavior codes 0 and 1) primary intracranial and central nervous system tumors (ICD-O-3 topography codes C70-C72) (1/1/1992).
3. Carcinoid, NOS of the appendix C181 (as of 1/1/2015).	3. As of 01/01/2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.	3. Early or evolving melanoma in situ, or any other early or evolving melanoma (2021+).	3 Non-malignant (behavior codes 0 and 1) primary endocrine glands and related structures (ICD-O-3 Topography codes C75.1-C75.3) (1/1/2007).
	4. Carcinoid, NOS of the appendix C181 (as of 1/1/2015).	4. Carcinoid, NOS of the appendix C181, behavior changed to 3 effective 2015 (2015+).	4. Non- malignant Borderline (behavior code 1) (all topographies in ICD-O-3) (1/1/1992 to 12/31/2020). Non- malignant Borderline (behavior code of 1) for these histology/ topography ICD-O-3 codes (9761/1, 9765/1, 9970/1) and (8442/1, 8472/1 with C56.9 only). (01/01/2021-forward)
	5. All GIST are reportable as of 01/01/2021 except for those specifically stated to be benign. The behavior code for GIST is /3 in ICD-O-3.2.	5. GIST tumors, all histologies changed to behavior 3 in ICD-O-3.2 (2021+).	5. Carcinoid, NOS of the appendix C181 (as of 1/1/2012).
	6. Nearly all thymomas are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2. The exceptions are microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0).	6. Thymomas, most behaviors changed to 3 in ICD-O-3.2. (2021+) See exceptions listed below.	6. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features, NIFTP, Non-invasive encapsulated follicular variant of papillary thyroid carcinoma EFVPTC, (8343/2 with C73.9) (1/1/2017-12/31/2020).
	7. Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast C500-C509 (as of 1/1/2016).	7. Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast C500-C509 (/2016+).	7. Low-grade appendiceal mucinous neoplasm (LAMN) behavior changed to 2 effective 2022 (1/1/2022).
	8. Pancreatic intraepithelial neoplasia (PanIN III) (as of 1/1/2016).	8. Pancreatic intraepithelial neoplasia (PanIN III) (2016+).	8. High-grade appendiceal mucinous neoplasm (HAMN) behavior changed to 2 effective 2022 (1/1/2022).
	9. Penile intraepithelial neoplasia III (PeIN III) (as of 1/1/2016).	9. Penile intraepithelial neoplasia III (PeIN III) (2016+).	9. Appendiceal mucinous neoplasm with extra-appendiceal spread, behaviour changed to 3 effective 2022 (1/1/2022).
	10. Clear cell papillary renal cell carcinoma 8323/3 is reportable. The 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs, 4^th Edition, has reclassified this histology as a /1 because it is low nuclear grade and is now thought to be a neoplasia. This change has not yet been implemented and it remains reportable.	10. Low-grade appendiceal mucinous neoplasm (LAMN) behavior changed to 2 effective 2022 (2022+).
	11. Low-grade appendiceal mucinous neoplasm (LAMN) now has a behavior of /2 and /3 making it reportable. /2 = Tis(LAMN) confined by muscularis propria (T1-T2 are not used for LAMN), and such lesions are designated as Tis /3 = T3-T4 extending into subserosa or serosa. The ICD-O Committee and authors of the WHO Classification of Tumors of the Digestive System, 5^th Edition agreed to issue corrigenda. Corrigenda – Appendiceal mucinous neoplasm 8480/2 Low-grade appendiceal mucinous neoplasm 8480/2 High-grade appendiceal mucinous neoplasm 8480/3 Appendiceal mucinous neoplasm with extra-appendiceal spread.	11. High-grade appendiceal mucinous neoplasm (HAMN) behavior changed to 2 effective 2022 (2022+).

Reportable Diagnoses

* Juvenile astrocytomas should be reported as 9421/3.

CoC	SEER	NPCR	CCCR
1. Skin cancers (C44._) with histology 8000-8110 (after 1/1/2003); prior to that date, AJCC stage groups 2-4 in this group were reportable.	1. Skin cancers (C44._) with histologies 8000-8005, 8010-8046, 8050-8084, 8090-8110.	1. Skin cancers (C44._) with histologies 8000-8005, 8010-8046, 8050-8084, 8090-8110.	1. Skin cancers (C44._) with histologies 8050-8084, 8090-8110 (1/1/1992).
2. CIS of the cervix and CIN III or SIN III (after 1/1/96).	2. CIS of the cervix and CIN III or SIN III of cervix (after 1/1/96).	2. CIS of the cervix and CIN III or SIN III.	2. Skin cancers (C44._) with histologies 8000-8005, 8010-8046 (1/1/2007).
3. PIN III (after 1/1/96).	3. PIN III (after 1/1/2001).	3. PIN III (2001+).	3. CIS of the cervix and CIN III or SIN III. (1/1/2007).
4. VIN III (after 1/1/96).	4. High grade dysplasia of the colon is not reportable even though it has been designated in situ (/2) in the latest WHO classification.	4. Colorectal tumors with the following morphologic description: Serrated dysplasia, high grade; Adenomatous polyp, high grade dysplasia; Tubular adenoma, high grade; Villous adenoma, high grade; Tubulovillos adenoma, high grade.	4. PIN III of the prostate (1/1/2007).
5. VAIN III (after 1/1/96).	5. There are two new histology codes for HPV-related adenocarcinoma in situ of the cervix. These are not reportable.	5. Microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0).	5. In situ (behaviour code of 2 in ICD-O-3) of the colon and rectum with histology 8148 (1/1/2019).
6. AIN (after 1/1/96).
7. 8210/2 Adenomatous polyp, high grade dysplasia (C160 – C166, C168-C169, C170-C173, C178-C179)
8. 8211/2 Tubular adenoma, high grade
9. 8261/2 Villous adenoma, high grade
10. 8263/2 Tubulovillous adenoma, high grade
11. 8483/2 Adenocarcinoma in situ, HPV-associated (C530-C531, C538-C539)
12. 8484/2 Adenocarcinoma in situ, HPV-independent, NOS (C530-C531, C538-C539)
13. 8509/1 Uterine tumor resembling ovarian sex cord tumor
14. 9200/1 Osteoblastoma
15. 9261/1 Osteofibrous dysplasia-like adamantinoma.
16. 8520/2 Lobular carcinoma in situ of the breast (C50.0-C50.9) (after 01/01/2018)

Exceptions (not reportable)

CoC	SEER	NPCR	CCCR
apparent(ly) appears comparable with compatible with consistent with favors malignant appearing most likely presumed probable suspect(ed) suspicious (for) typical of Exception: if the cytology is reported using any of these ambiguous terms and neither a positive biopsy nor a physician's clinical impression supports the cytology findings, do not consider as diagnostic of cancer.	apparent(ly) appears comparable with compatible with consistent with favors malignant appearing most likely presumed probable suspect(ed) suspicious (for) typical of Exception: if the cytology diagnosis is reported using any of these ambiguous terms and neither a positive biopsy nor a physician's clinical impression supports the cytology findings, do not report.	apparent(ly) appears comparable with compatible with consistent with favors malignant appearing most likely presumed probable suspect(ed) suspicious (for) typical of Exception: if the cytology is reported using any of these ambiguous terms and neither a positive biopsy nor a physician's clinical impression supports the cytology findings, do not consider as diagnostic of cancer.	apparent(ly) appears comparable with compatible with consistent with favors malignant appearing most likely presumed probable suspect(ed) suspicious (for) typical of Exception: if the cytology is reported using any of these ambiguous terms and neither a positive biopsy nor a physician's clinical impression supports the cytology findings, do not consider as diagnostic of cancer.

Ambiguous Terminology Diagnostic of Cancer**

** Do not substitute synonyms such as “supposed” for “presumed” or “equal” for “comparable.” Do not substitute “likely” for “most likely.” Use only the exact words on the list.

CoC	SEER	NPCR	CCCR
cannot be ruled out equivocal possible potentially malignant questionable rule out suggests worrisome	Any ambiguous terms not on the reportable list are not reportable.	cannot be ruled out equivocal possible potentially malignant questionable rule out suggests worrisome	cannot be ruled out equivocal possible potentially malignant questionable rule out suggests worrisome

Ambiguous Terminology NOT Diagnostic of Cancer**